Skip to main content
Premium Trial:

Request an Annual Quote

Myriad Genetics Using BRACAnalysis as CDx for Tesaro Cancer Drug

NEW YORK (GenomeWeb News) – Myriad Genetics said after the close of the market on Monday that it has signed an agreement to provide its BRACAnalysis test as a companion diagnostic for a cancer therapeutic being developed by Tesaro.

Under the terms of the deal, the BRCA1 and BRCA 2 test will be used in two separate Phase III clinical trials with niraparib, a novel, orally active poly (ADP ribose) polymerase, or PARP, inhibitor. One trial, in platinum-sensitive, high-grade serous ovarian cancer patients, is slated to begin enrollment in the middle of this year. A second trial, in metastatic breast cancer patients who have germline BRCA mutations, will begin in the second half of the year.

"We believe this agreement reinforces BRACAnalysis as the gold standard companion diagnostic test for this exciting new class of therapeutics," Myriad President and CEO Peter Meldrum said in a statement.

Financial and other terms of the deal were not disclosed.

Myriad recently submitted an investigational device exemption application with the US Food and Drug Administration for BRACAnalysis, laying the regulatory groundwork for the test to be studied in five pivotal trials to pick out best responders to AstraZeneca's PARP inhibitor olaparib, according to Pharmacogenomics Reporter. While it is Myriad's first IDE submission, the firm has companion diagnostic deals with several other biopharma firms, including Abbott Laboratories, Cephalon, BioMarin, and PharmaMar.

The agreement with Tesaro comes on the heels of the US Supreme Court's decision two weeks ago that isolated human genes are not patentable — a case that centered on Myriad's patents covering the BRCA1 and BRCA2 genes. The court, however, found that synthetic DNA is patent eligible.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.